Redeye briefly comments on Cinclus’ announcement that the first patient has been dosed in its pivotal phase III study with linaprazan glurate in erosive GERD. We see this as an important operational milestone confirming that the program is progressing according to plan, positioning Cinclus well ahead of the topline results expected in H2 2026e.

Läs mer på Redeye

Ämnen i artikeln


Cinclus Pharma

Senast

11,90

1 dag %

−1,49%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån